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Abstract
Background: Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis.
However, MYCN-amplification does not automatically result in higher expression of MYCN in children with
NB. We hypothesized that the discrepancy between MYCN gene expression and prognosis in these
children might be explained by the expression of either MYCN-opposite strand (MYCNOS) or the
shortened MYCN-isoform (ΔMYCN) that was recently identified in fetal tissues. Both MYCNOS and
ΔMYCN are potential inhibitors of MYCN either at the mRNA or at the protein level.
Methods: Expression of MYCN, MYCNOS and ΔMYCN was measured in human NB tissues of different
stages. Transcript levels were quantified using a real-time reverse transcriptase polymerase chain reaction
assay (QPCR). In addition, relative expression of these three transcripts was compared to the number of
MYCN copies, which was determined by genomic real-time PCR (gQPCR).
Results: Both ΔMYCN and MYCNOS are expressed in all NBs examined. In NBs with MYCN-amplification,
these transcripts are significantly higher expressed. The ratio of MYCN:ΔMYCN expression was identical
in all tested NBs. This indicates that ΔMYCN and MYCN are co-regulated, which suggests that ΔMYCN is
not a regulator of MYCN in NB. However, the ratio of MYCNOS:MYCN expression is directly correlated
with NB disease stage (p = 0.007). In the more advanced NB stages and NBs with MYCN-amplification,
relatively more MYCNOS is present as compared to MYCN. Expression of the antisense gene MYCNOS
might be relevant to the progression of NB, potentially by directly inhibiting MYCN transcription by
transcriptional interference at the DNA level.
Conclusion: The MYCNOS:MYCN-ratio in NBs is significantly correlated with both MYCN-amplification
and NB-stage. Our data indicate that in NB, MYCN expression levels might be influenced by MYCNOS but
not by ΔMYCN.
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Background
Neuroblastoma cells (NBs) that carry an amplified MYCN
gene are extremely malignant. However, MYCN-amplifi-
cation does not automatically result in higher expression
of MYCN in children with NB [1-3]. Thus, it has been sug-
gested that the aggressive phenotype of MYCN amplified
NBs may be explained by higher expression levels of other
genes co-amplified with MYCN, since the amplified unit
of DNA can be up to 1 Mb. To date, three genes have been
identified that are frequently co-amplified with MYCN in
NBs: DDX1 in 50% of the cases, NAG in 20% of the
tumours, and MYCNOS in all cases [4,5]. All three genes
demonstrate increased transcript expression when co-
amplified in NB cell lines, indicating that they may con-
tribute to tumour phenotype. However, survival analyses
in a large study using 75 MYCN-amplified tumours indi-
cate that neither amplified DDX1 nor NAG have an addi-
tional adverse effect on the prognosis of the patients [6].
Natural antisense transcripts are abundant in eukaryotic
genomes [7-9]. In human, more than 1600 natural anti-
sense transcript are predicted to be present [10]. They can
influence gene expression on the DNA level by transcrip-
tional interference, on the transcript level by RNA interfer-
ence and RNA editing, or direct splicing by RNA masking
[11,12]. MYCNOS is the antisense transcript of MYCN
[13] and shows overlap with the first exon of MYCN. This
antisense transcript could be involved in modulating the
expression of MYCN by any of the mechanisms men-
tioned above. Antisense transcripts are considered to be
relevant to the development and progression of tumours
[14-16], but until now, only antisense HIF-1α RNA has
been shown to be a marker for prognosis in human breast
cancer [17].
Recently, we reported a fetal MYCN splice variant
(ΔMYCN) lacking exon 2 [18]. The ΔMYCN transcript is
expressed in several fetal tissues and contains the acidic
region, nuclear localization signal, the basic helix-loop-
helix and leucine-zipper domains but lacks the transacti-
vation domain. It has been suggested that the ΔMYCN
protein may serve as an obligate dimerization partner for
MYCN to convey transcriptional activation or repression.
In this report we analysed whether expression of ΔMYCN
and MYCNOS influence MYCN expression levels in NBs
of different disease stages.
Methods
Tumour material
Sixteen fresh-frozen NBs were obtained from at the
Department of Pathology at the Radboud University
Nijmegen Medical Centre. All NBs were derived from
pediatric patients (0 to 6-years-old) diagnosed at the
Department of Pediatric Hemato-Oncology. Sections of
the frozen samples were stained with hematoxylin-eosin
and reviewed by the pathologist to verify tumour histol-
ogy and to evaluate the percentage of tumour cells. Sam-
ples were only considered for study if the contents of
tumour cells was ≥ 75%. Six out of 16 NBs had MYCN-
amplification as shown by southern blot and/or fluores-
cent in situ hybridization (FISH). All samples were ano-
nymized prior to this study, and the research program was
approved by the local ethics committee (Commissie
Mensgebonden Onderzoek Regio Arnhem-Nijmegen).
DNA isolation, RNA isolation and cDNA synthesis
Tumour samples were aliquoted in two parts to isolate
both DNA and RNA. Total DNA was isolated with the
QIAamp isolation-kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer's protocol. All samples were
RNAse treated. Total RNA was isolated with TriZol reagent
(Invitrogen, Carlsbad, CA, USA) and treated with Deoxyri-
bonuclease I (Dnase I; Invitrogen). DNase-treated RNA
was reverse-transcribed using oligo(dT) primers with the
SuperScript First-Strand Synthesis System (Invitrogen).
PCR
MYCN and splice variants were amplified from cDNA by
using the GC-RICH PCR System (Roche Applied Science,
Almere, The Netherlands). Primers were developed by the
primer3 program (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi[19]). Primer sequences are
shown in table 1 and the position of the primers in MYCN
are depicted in figure 1. PCR products were sequenced
using the ABI PRISM BigDye Terminator Cycle Sequenc-
ing V2.0 Ready Reaction Kit and analysed with the ABI
PRISM 3730 DNA analyser (Applied Biosystems, Foster
City, CA, USA).
QPCR and gQPCR
QPCR and gQPCR was performed by SYBR Green-based
quantification (Bio-Rad, Veenendaal, The Netherlands).
PCRs were performed on an iCycler (MyiQ single color
Real-Time detection System, Bio-Rad, Veenendaal, The
Netherlands). Sequences of the primers used to quantify
cDNA transcript levels and genomic DNA are shown in
table 1 and the position of the primers is depicted in fig-
ure 1. PCR products were between 80- and 100-bp. Vali-
dation of the primer pairs and (g)QPCR experiments were
performed as described previously [20,21]. Differences in
expression of a gene of interest or in genomic DNA copy
number between two samples were calculated by the com-
parative Ct or 2ΔΔCt method [22,23]. Hoebeeck et al.
described and validated a similar assay for the determina-
tion of MYCN copy numbers in tumor samples [24].
Antibody coupling and immunoprecipitation
NB-samples were homogenized in RIPA-buffer (50 mM
Tris-HCl pH 7.4, 0.2% sodium dodecyl sulfate (SDS),
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0.2% sodium deoxycholate, 1% triton X-100, 1 mM
EDTA) supplemented with 1 mM DTT, 1 mM PMSF, apro-
tinin 2 μg/ml and leupeptin 2 μg/ml. Total protein con-
centration was determined according to the Bradford
method (Bio-Rad Laboratories, Hercules, CA, USA).
For immunoprecipitation, 5 μg C-19 mAb (Santa Cruz
Biotechnology, Heidelberg, Germany) was coupled to
Prot A sepharose CL-4B beads (Pharmacia Biotechnolo-
gies, Uppsala, Sweden) for 1 hour at 4°C to). NB-lysates
were precleared O/N with 50 μl packed Prot A sepharose
CL-4B beads. To the precleared lysates, 20 μl C-19-cou-
pled beads was added and incubated for 24 h at 4°C. Sub-
sequently, the beads were washed with PBS and
resuspended in SDS sample buffer and stored at -80°C
until SDS-polyacrylamide gel electrophoresis (PAGE).
SDS-PAGE and Western blotting
Samples (30 μg homogenized NB-sample or 20 μl precip-
itation beads) were separated a 10% polyacrylamide gels
and transferred to nitrocellulose (Hi-bond, Amersham
Biosciences, Little Chalfont, UK). Ponceau S staining was
used to confirm that equal amounts of protein were
loaded in each lane (additional file 1). The nitrocellulose
blot was blocked with 1% BSA in 20 mM Tris-HCl pH 7.4
and 0.1% Tween (Tris-buffered saline/Tween 20; TBS-T)
for 1 h. The blot was washed for 5 min with TBS-T fol-
lowed by incubation with the C-19 anti-MYCN antibody
1:200 diluted in TBS-T for 1 h at RT. After washing 3× with
TBS-T, the blot was incubated with HRP-conjugated
swine-anti-rabbit antibody (1:5000 diluted in TBS-T) for
1 h at RT. Subsequently, the blot was washed and incu-
bated for 1 min with ECL substrate (Amersham Bio-
sciences, Little Chalfont, UK) and exposed to film (Kodak,
Rochester, NY, USA).
Overexpression of MYCNOS in the NB cell line IMR-32
Primers for the amplification of MYCNOS were developed
by using the primer3 program (Table 1). MYCNOS was
amplified from DNA isolated from a healthy control using
the GC RICH PCR System (Roche, Woerden, The Nether-
lands). Subsequently, MYCNOS was cloned into the Gate-
way donor vector pDONR-201 (Invitrogen). Using the
Gateway cloning system, MYCNOS was subsequently sub-
cloned into the pcDNA3 expression vector and integrity of
the construct was validated by sequence analysis. IMR-32
NB cells at 50% confluence in a 25 cm2 flask were co-
transfected with 8 μg pcDNA3-MYCNOS and C1-GFP
using 120 μl lipofectamine (Invitrogen) in 3 ml Opti-
MEM-I for 20 min at RT.
Schematic overview of (A) genomic organization, (B) transcripts, and (C) protein isoforms of MYCN and MYCNOSFigure 1
Schematic overview of (A) genomic organization, (B) transcripts, and (C) protein isoforms of MYCN and MYC-
NOS. The localization of primer sites (small arrows) and the C-19 antibody epitope are indicated. (D) RT-PCR with primers 
on exon 1 and 3 on NB cDNA of patient 13 and NB cell line IMR-32 give products of 1007 bp (MYCN) and 100 bp (ΔMYCN). 
The identity of both products was verified by sequence analysis.
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Table 1: Primer-sequences of primers used in this report.
Gene of interest Genbank ID Forward primer Reverse primer
QPCR
MYCN NM_005378.4 5'-cacaaggccctcagtacctc-3' 5'-accacgtcgatttcttcctc-3'
ΔMYCN Not present 5'-cagaatcgcctccggatc-3' 5'-cgcttctccacagtgacca-3'
MYCNOS S49953.1 5'-tccgacagctcaaacacagac-3' 5'-ccagctttgcagccttctc-3'
MYCN total NM_005378.4 5'-cataaggggtttgccatttg-3' 5'-ctaatactggccgcaaaagc-3'
GUSB NM_000181.1 5'-agagtggtgctgaggattgg-3' 5'-ccctcatgctctagcgtgtc-3'
TFRC NM_003234.1 5'-gttcttctgtgtggcagttcag-3' 5'-caggctgaaccgggtatatg-3'
RNFIII NM_017610.6 5'-gcagaatgcagcagaagttg-3' 5'-ccattcttgcagaagtggttg-3'
gQPCR
MYCN (exon 1) NM_005378.4 5'-ccgggtgtgtcagatttttc-3' 5'-tccaacacagttcccaggag-3'
MYCN (exon 2) NM_005378.4 5'-gatctgcaagaacccagacc-3' 5'-ccgccgaagtagaagtcatc-3'
MYCN (exon 3) NM_005378.4 5'-gttcctcctccaacaccaag-3' 5'-aggcatcgtttgaggatcag-3'
MYCN (3'-UTR) NM_005378.4 5'-taccaggtgcaggagagacc-3' 5'-agcccaagtagccaagacac-3'
MYCNOS S49953.1 5'-aagaagggtagtccgaaggtg-3' 5'-gaaactggaaacatccagagg-3'
CFTR NM_000492.3 5'-gggtcttgataaatggcttcc-3' 5'-tctggcttgcaaaacacaag-3'
TBX22 NM_016954.2 5'-tttaccggctcctgaaagac-3' 5'-aaccgctttttgaattggtg-3'
SLC16A2 NM_006517.2 5'-cttcttcgtccctctgatgc-3' 5'-tcaggggccaacatcttatc-3'
Cloning
MYCNOS S49953.1 5'-agggggtggtggcgaggc-3' 5'-gtagctcgcacttatttatttat-3'
Table 2: Patient characteristics.
Pt Agea Sex Diagnosis Localization Histologyb MYCNc Treatment and follow-up Status
1. 3 mnts F NB IV S Adnex and liver metastasis UD No 05/'01 surgery + chemo Alive
2. 3 yrs M NB IV Supraclavicular and BM metastases PD No 02/'03 surgery + chemo
07/'03 chemo, SCR + RT
Alive
3. 4 mnts M NB II Pos. lymphnodes with unknown primary 
tumor
PD No 01/'03 surgery + chemo Alive
4. 5 mnts M NB IV S Spine and bone/liver metastases PD No 01/'01 surgery + chemo Alive
5. 14 mnts F NB II Spine PD No 02/'04 surgery + chemo Alive
6. 4 mnts F NB II Adnex PD No 07/'01 surgery + chemo Alive
7. 2 yrs F NB III Adnex D No 01/'02 chemo + sugery Alive
8. 3 mnts M NB I Adnex D No 02/'02 Surgery Alive
9. 2 yrs M NB IV Adnex with bone/BM metastases Dd No 12/'03 chemo, SCR + RT
10/'04 relapse treatment
d.o.d.
10. 8 mnts F NB III Spine PD No 04/'02 surgery + chemo
12/'02 Surgery spinal relapse
Alive
11. 18 mnts F NB III Adnex UDd 20× 09/'98 MIBG, chemo + surgery
04/'99 chemo and SCR
d.o.d.
12. 2 yrs M NB IV Adnex and bone metastases PDd 37 × 07/'98 surgery, chemo + SCR d.o.d.
13. 6 yrs M NB III Adnex UD 27 × 01/'00 surgery, chemo + SCR
11/'03 surgery, chemo + RT
d.o.d.
14. 19 mnts M NB IV Adnex and spine metastasis UD 49 × 03/'98 MIBG, chemo + surgery d.o.d.
15. 18 mnts M NB IV Adnex and multiple distal metastases n.d. 139 × 06/'99 chemo + RT d.o.d.
16. 16 mnts M NB IV Adnex and multiple distal metastases UD 74 × 01/'97 chemo + surgery d.o.d.
aAge at diagnosis
bNeuroblastoma differentiation as assessed by pathologist. D = differentiated; PD = poorly differentiated; UD = undifferentiated
cMYCN genomic amplification, as determined with qPCR
dPatient has been treated before surgery
BM = bone marrow; d.o.d. = death of disease; MIBG = meta-iodobenzylguanidine; SCR = stem cell rescue; RT = radiotherapy.
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Statistical analysis
Statistically significant differences in expression of MYCN-
transcripts between NBs with or without MYCN-amplifi-
cation were calculated with Students' T-test. Correlation of
MYCN-transcipt expression with disease stage was calcu-
lated using the Spearman rank correlation and correlation
of MYCN-transcripts with the MYCN-amplification num-
bers was calculated with the Pearson correlation test. All
statistical tests were two-sided, significance was deter-
mined as p < 0.05.
Results
Patient characteristics
We analysed fresh-frozen NBs from 16 pediatric patients
(age range: 0–6 years old). The NBs are classified accord-
ing to the Children's Cancer Group Neuroblastoma Stag-
ing System [25] and treated according to Pediatric
Oncology Group-protocols (Table 2). Six out of 16 NBs
carried a MYCN-amplification initially detected by South-
ern blot and/or FISH.
ΔMYCN expression in the neuroblastoma cell line IMR-32
Two splice variants have been described for the proto-
oncogene MYCN, the classical transcript that consists of
three exons and a shortened ΔMYCN transcript that lacks
exon 2. ΔMYCN is expressed in several fetal tissues, but its
expression has not been reported in NBs. We used primers
spanning exon 2 (Figure 1A and Table 1) to visualize by
reverse transcriptase PCR whether or not both transcripts
are present in MYCN-amplified IMR-32 neuroblastoma
cells. Two fragments were identified that corresponded
with the expected product lengths of MYCN and ΔMYCN
of respectively 1007 and 100 bp (Figure 1D). Sequence
analyses on the excised products confirmed that these
fragments were MYCN and ΔMYCN. Absence of addi-
tional fragments in the IMR-32 NB cell line suggests that
there are no other major MYCN splice variants. To deter-
mine whether the ΔMYCN protein is expressed in IMR-32
NB cells, MYCN proteins were visualized with the C-19
antibody that recognizes the c-terminal epitope of both
MYCN and ΔMYCN proteins. In the lysate of IMR-32 cells,
two protein bands were recognized at approximately 65
and 45 kD, which are the predicted molecular weights of
MYCN and ΔMYCN respectively [18] (Figure 2A). For
comparison, in a lysate of the melanoma cell line (BLM),
which does not carry MYCN-amplification, no reactivity
could be observed. We conclude from these experiments
that the fetal MYCN isoform ΔMYCN is co-expressed with
MYCN in IMR-32 cells.
Quantitative analyses of MYCN, ΔMYCN and MYCNOS 
expression levels in neuroblastomas
mRNA expression levels of MYCN, ΔMYCN and MYCNOS
were measured in 16 human neuroblastoma samples
(Table 2) by QPCR relative to three reference genes:
GUSB, TFRC and RNFIII [21]. Both MYCN and MYCNOS
were found to be expressed in all 16 NBs. In addition,
ΔMYCN expression was detected in all NB samples, except
for patient 9, who did not carry an amplification of the
MYCN region. For MYCN, it has been demonstrated that
the relative expression-levels are significantly higher in
NBs with MYCN-amplification as compared to non-
amplified tumours [26]. Here, we show that besides
MYCN, the relative mRNA expression levels of ΔMYCN
and MYCNOS are also significantly increased in NBs with
MYCN-amplification (p < 0.01; Figure 3A).
Correlation of NB stage with MYCN:ΔMYCN-ratio
showed that the MYCN:ΔMYCN-ratio remains constant
and does not change with either MYCN-amplification
Detection of MYCN and ΔMYCN in IMR-32 cellsFigure 2
Detection of MYCN and ΔMYCN in IMR-32 cells. (A) Western blot, visualizing two proteins in the IMR-32 (NB cell line 
with MYCN-amplification) lysate with the C-19 antibody that recognizes the C-terminal epitope of both MYCN and ΔMYCN. 
In the BLM (melanoma cell line without MYCN-amplification) lysate, these proteins were not present. (B) Western blot of IMR-
32 whole lysate (1), whole lysate minus precipitate (2) and the precipitate (3) using the C-19 antibody. Arrows indicate the 
positions of MYCN (65 kDa) and ΔMYCN (45 kDa). The additional band in lane 3 is caused by deposition of Ig-heavy chains 
(50 kDa). Exposure times are indicated below the blots.
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MYCN, ΔMYCN, and MYCNOS mRNA expression levels in NBsFigure 3
MYCN, ΔMYCN, and MYCNOS mRNA expression levels in NBs. (A) Expression levels of MYCN, ΔMYCN and MYCNOS 
in MYCN-amplified (closed-triangles) compared to non-amplified (open triangles) tumours. (B) Relative expression-levels of 
MYCN (closed triangles), ΔMYCN (closed circles) and MYCNOS (open circles) correlated to MYCN-amplification in NBs. (C) Dif-
ference of the MYCN:MYCNOS-ratio between NBs with MYCN-amplification (closed circles) and NBs without MYCN-amplifica-
tion (open circles). (D) Correlation of the number of MYCN copies with MYCN:MYCNOS mRNA ratios (closed circles and non-
interrupted line) and with MYCN:MYCN mRNA ratios (open triangles and dotted line). (E) Correlation between NB stage and 
MYCN:MYCNOS-ratio. (F) Correlation between NB stage and MYCN: ΔMYCN-ratio. NB IV-s is a special type of NB character-
ized by metastatic disease with spontaneous regression and good survival [31].
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(Figure 3C; two-tailed p-value = 0.09, calculated with the
Students' T-test) or NB stage (Figure 3F; two-tailed p-value
= 0.12, calculated with the Spearman rank correlation).
However, there is a significant correlation between the
MYCN:MYCNOS-ratio and both MYCN-amplification
(Figure 3C; two-tailed p-value = 0.025) and NB-stage (Fig-
ure 3E; two-tailed p-value = 0.007). The MYC-
NOS:ΔMYCN-ratio did not significantly change with
either MYCN-amplification or NB-stage (two-tailed p-val-
ues = 0.58 and 0.24, respectively; data not shown). These
data show that in more advanced NB tumours, mRNA
expression of MYCNOS increases relative to MYCN.
ΔMYCN and MYCNOS expression relative to level of 
MYCN-amplification
To more exactly determine MYCN copy number in the
tumours that were studied, we performed a genomic
quantitative PCR (gQPCR) using genomic primers recog-
nizing five different locations within the MYCN-gene (Fig-
ure 1A; Table 1). Amplification of these DNA fragments
was calculated relative to three reference genes elsewhere
on the genome, CFTR, TBX22, and SLC16A2. Among
these three reference genes, there were no copy number
differences noted in any of the NB samples. All 10 samples
with a normal MYCN-copy number based on Southern
blotting and/or FISH, carried two to four MYCN copies as
determined by gQPCR. The presence of a MYCN duplica-
tion in NB cells that lack an overt amplification of MYCN
is more often found, although the implications for the
progression of the NB are still unclear [5,27]. All 6 sam-
ples with multiple copies of MYCN, as determined by
Southern blotting and/or FISH, had in between 20 and
139 MYCN gene amplifications (Table 2), which is within
the normal range of gene copy numbers observed in NBs
with MYCN-amplification [28].
We observed that MYCN mRNA-expression does not line-
arly correlate with MYCN-amplification, consistent with
earlier reports [26]. In addition, also ΔMYCN and MYC-
NOS do not correlate linearly with the number of MYCN
gene copies (Figure 3B). As shown in figure 3D, the rela-
tive mRNA expression ratio of MYCN:MYCNOS decreases
with an increasing number of MYCN gene copies
although this is not significant (non-interrupted line,
slope = -0.4; two-tailed p-value = 0.18, calculated with the
Pearson correlation test). The MYCN:ΔMYCN ratio does
not change with higher MYCN copy numbers (Figure 3D;
dotted line, slope = -0.1; two-tailed p-value = 0.88).
Overexpression of MYCNOS in the NB cell line IMR-32
The pre-mRNA of MYCNOS, which represents the MYCN
antisense transcript, shows overlap with the first exon of
MYCN. Therefore MYCNOS may potentially modulate
MYCN mRNA expression levels at the mRNA level via
RNA-interference or RNA-editing, or direct MYCN splic-
ing by RNA masking [11]. To test this premise, we trans-
fected IMR-32 NB cells with C1-GFP and either the
pcDNA3-vector containing MYCNOS or an empty vector.
IMR-32 cells have relatively high endogenous expression
levels of MYCN, MYCNOS and ΔMYCN, which enables
quantification of all three mRNA levels. Flow cytometric
analyses showed that there was a transfection efficiency of
74% after 72 hours (Figure 4A). Although there was a 50-
fold increase of MYCNOS gene expression in the MYC-
NOS-transfected cell line relative to the empty vector con-
trol cell line (Figure 4B), expression of endogenous MYCN
and ΔMYCN was not affected either at the mRNA level or
at the protein level (Figure 4B, C). We conclude that
although increased expression of MYCNOS relative to
MYCN is correlated with an advanced disease state, RNA-
interference or RNA-editing are not the mechanisms by
which MYCNOS downregulates MYCN expression. In
addition, the unchanged MYCN:ΔMYCN ratio in cells
with MYCNOS overexpression shows that MYCNOS does
not affect splicing by RNA-masking.
Discussion
In this report, we have analysed the expression levels of
MYCN, ΔMYCN and MYCNOS in NBs. We find that these
three mRNA transcripts are expressed in NBs of all stages,
but more highly in NBs with MYCN-amplification. The
MYCN:MYCNOS expression level ratio is significantly
decreased in high grade NBs, whereas the MYCN:ΔMYCN
remains constant in NBs of all stages, which indicates that
MYCN and ΔMYCN are co-regulated. These results suggest
that MYCNOS might be involved in the regulation of
MYCN expression levels as has been shown for numerous
other antisense transcripts regulating expression of their
sense counterparts [11,12]. However, it is important to
note that the number of NB samples we investigated is rel-
atively small. Future studies in larger cohorts of patients
are needed to further establish a role for MYCNOS in the
regulation of MYCN expression in patients with low-,
intermediate- and high-risk NB.
Natural antisense RNA can inhibit gene expression at the
DNA level by transcriptional interference or at the mRNA
level by RNA-interference or RNA-editing, or regulate
splicing by RNA-masking [11,12]. In RNA-masking,
MYCN-MYCNOS duplex formation modulates RNA
processing by preserving a MYCN population that retains
intron 1, hence resulting in decreased ΔMYCN expression.
Krystal et al. [29] showed that RNA-masking can occur,
but they found that only approximately 5% of MYCN
RNA interacts with MYCNOS RNA. Our results show that
it is unlikely that MYCNOS expression has an effect on
splicing, since 50-fold overexpression of MYCNOS in
IMR-32 cells did not change the MYCN/ΔMYCN expres-
sion ratio at the mRNA level. Therefore, inhibition of
(Δ)MYCN expression seems to be the most likely role for
BMC Cancer 2009, 9:239 http://www.biomedcentral.com/1471-2407/9/239
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MYCNOS. There are three mechanisms by which this may
be accomplished: transcriptional interference, RNA inter-
ference and RNA-editing. Since our results show that over-
expression of MYCNOS pre-mRNA in NB cell line IMR-32
does not suppress MYCN expression, RNA-interference
and RNA-editing do not seem to be the primary inhibitory
mechanisms, leaving the possibility that regulation occurs
at the DNA level by steric hindrance of the voluminous
RNA-polymerase complexes on opposite DNA strands.
It is not clear how increased expression of MYCNOS con-
tributes to the development of NB. Although the increase
of MYCNOS expression levels is higher than that of MYCN
in NB with amplification, this difference does not appear
to influence the prognosis of patients. In patients with NB
but without MYCN-amplification, it would be interesting
to investigate whether the MYCN:MYCNOS ratio is a good
prognostic marker. Differences in MYCNOS expression
levels might explain some of the controversies about
MYCN expression and prognosis of these patients [1-3].
Besides MYCN and MYCNOS, ΔMYCN, which was previ-
ously identified as a fetal transcript [18], is also expressed
in NBs. No other MYCN isoforms were detected. This sug-
gests that the alternative splice variant that previously has
been described by Stanton et al. [30] and consists of an
alternatively spliced exon 1, has little relevance in the pro-
gression of NBs. In one tumour, the ΔMYCN transcript
could not be identified, but this is probably because
ΔMYCN is low expressed in general and in this tumour
MYCN was not amplified. The ΔMYCN protein contains a
nuclear localization signal, a basic helix-loop-helix, and a
Overexpression of MYCNOS in the NB cell line IMR-32Figure 4
Overexpression of MYCNOS in the NB cell line IMR-32. (A) Transfection-efficiency was measured by GFP expression as 
analysed by flow cytometry, 74% of the NB cells expressed GFP 72 hours after transfection. (B) In the MYCNOS transfected 
IMR-32 cells, MYCNOS was 50× upregulated compared to not transfected and mock-transfected IMR-32 cells. Endogenous 
MYCN expression was not significantly affected. (C) Western blot showing that MYCN protein expression in MYCNOS trans-
fected IMR-32 cells was unaffected. Lane 1 is loaded with lysate from untransfected cells, lane 2 with lysate from cells trans-
fected with the empty vector, and lane 3 with lysate from MYCNOS transfected cells.
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leucine-zipper domain, which may serve to dimerize with
MYCN or bind to its DNA binding site. ΔMYCN lacks the
transactivation domain including the highly conserved
Myc 1 and 2 boxes, from which it was speculated that it
competes with MYCN and therefore inhibits the active
MYCN protein [18]. However, in all neuroblastoma sam-
ples analyzed, the ratio between MYCN and ΔMYCN
expression remains constant and does not correlate with
MYCN-amplification or disease stage, indicating that
ΔMYCN induced inhibition of MYCN at the protein level
is not of relevance in NB.
Conclusion
In conclusion, our results suggest that the expression of
the antisense gene MYCNOS might be relevant to the pro-
gression of NB, potentially by directly inhibiting MYCN
transcription by transcriptional interference at the DNA
level. Analysis of MYCN:MYCNOS expression ratios in
patients with NB without MYCN-amplification and clini-
cal follow-up are necessary to establish the relevance of
MYCNOS expression to the prognosis of these patients.
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